Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Inozyme Pharma stock | $25.93

Own Inozyme Pharma stock in just a few minutes.

Fact checked

Inozyme Pharma, Inc is a biotechnology business based in the US. Inozyme Pharma shares (INZY) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Inozyme Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Inozyme Pharma. Find the stock by name or ticker symbol: INZY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Inozyme Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$25.93, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Inozyme Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Inozyme Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Inozyme Pharma share price

Use our graph to track the performance of INZY stocks over time.

Inozyme Pharma shares at a glance

Information last updated 2021-01-11.
Latest market closeUSD$25.93
52-week rangeUSD$16.1 - USD$31.65
50-day moving average USD$24.2606
200-day moving average USD$24.2975
Wall St. target priceUSD$36.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.1071

Buy Inozyme Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Inozyme Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inozyme Pharma price performance over time

Historical closes compared with the close of $25.93 from 2021-01-11

1 week (2021-01-07) 1.73%
1 month (2020-12-16) 8.81%
3 months (2020-10-16) 11.82%
6 months (2020-07-13) N/A
1 year (2020-01-13) N/A
2 years (2019-01-13) N/A
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Inozyme Pharma financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$609.6 million

TTM: trailing 12 months

Shorting Inozyme Pharma shares

There are currently 340,891 Inozyme Pharma shares held short by investors – that's known as Inozyme Pharma's "short interest". This figure is 52.8% down from 721,615 last month.

There are a few different ways that this level of interest in shorting Inozyme Pharma shares can be evaluated.

Inozyme Pharma's "short interest ratio" (SIR)

Inozyme Pharma's "short interest ratio" (SIR) is the quantity of Inozyme Pharma shares currently shorted divided by the average quantity of Inozyme Pharma shares traded daily (recently around 31622.54174397). Inozyme Pharma's SIR currently stands at 10.78. In other words for every 100,000 Inozyme Pharma shares traded daily on the market, roughly 10780 shares are currently held short.

However Inozyme Pharma's short interest can also be evaluated against the total number of Inozyme Pharma shares, or, against the total number of tradable Inozyme Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inozyme Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Inozyme Pharma shares in existence, roughly 10 shares are currently held short) or 0.0146% of the tradable shares (for every 100,000 tradable Inozyme Pharma shares, roughly 15 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Inozyme Pharma.

Find out more about how you can short Inozyme Pharma stock.

Inozyme Pharma share dividends

We're not expecting Inozyme Pharma to pay a dividend over the next 12 months.

Inozyme Pharma overview

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site